一个扭曲的错误信息:伊维菌素应该被批准作为COVID-19疾病的治疗药物吗?

IF 2.1 4区医学 Q3 VIROLOGY

Future Virology Pub Date : 2023-02-01 DOI:10.2217/fvl-2023-0006

Arman Shafiee, Mohammad Mobin Teymouri Athar, Sayed-Hamidreza Mozhgani

引用次数: 0

摘要

这篇社论审查了导致围绕伊维菌素的证据如此有争议的原因，对最近发表的证据进行了简要分析，并强调了为什么从伊维菌素中吸取教训对未来重新利用药物很重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

A twisting tale of misinformation: should ivermectin be approved as a treatment for COVID-19 disease?

This editorial examines what has caused the evidence around ivermectin to be so controversial, provides a brief analysis of recently published evidence, and highlights why it is important to learn lessons from ivermectin for future re-purposed drugs.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Future Virology 医学-病毒学

CiteScore

4.00

自引率

3.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Future Virology is a peer-reviewed journal that delivers essential information in concise, at-a-glance article formats. Key advances in the field are reported and analyzed by international experts, providing an authoritative but accessible forum for this ever-expanding area of research. It is an interdisciplinary forum for all scientists working in the field today.